WallStreetZenWallStreetZen

How to Buy Cellectis Sa Stock

Cellectis Sa

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

Cellectis Sa stock last closed at $2.65, down 0.75% from the previous day, and has increased 30.22% in one year. It has overperformed other stocks in the Biotechnology industry by 0.35 percentage points. Cellectis Sa stock is currently +175.18% from its 52-week low of $0.96, and -29.76% from its 52-week high of $3.77.

There are currently 55.58M CLLS shares outstanding. The market cap of CLLS is $147.30M. In the past 24 hours, 44,022 CLLS shares were traded.

How to Buy Cellectis Sa Stock

Not sure how to invest in Cellectis Sa stock? Here's how.
  1. Choose where to buy Cellectis Sa stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Cellectis Sa stock.
  2. Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
  3. Deposit funds into your brokerage account: Choose your payment method and add your details.
  4. Analyze Cellectis Sa stock: The Cellectis Sa ticker symbol is CLLS. Is Cellectis Sa stock a good investment? Should you buy shares of CLLS? How do CLLS's underlying business fundamentals look? Do top analysts think Cellectis Sa is a good buy? Why has CLLS's stock price moved recently? (Hint: Our stock market research tools can help you evaluate if CLLS is a good stock to buy).
  5. Execute your CLLS trade: Decide if you will purchase CLLS shares at the current market price or use a limit order to purchase CLLS stock at a particular price.
  6. Keep tabs on your CLLS investment: Create a watchlist to important notifications about your new investment in Cellectis Sa shares.

Step 1: Choose where to buy Cellectis Sa stock

You need an online brokerage account in order to access the NASDAQ market and buy CLLS shares.

A brokerage account enables you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

Based on our analysis, eToro is the best brokerage. eToro gives you:

  • Invest in stocks with zero commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
  • Access to global financial markets: From Tech to Industrials, New York to London — you can fill your portfolio with stocks from the globe's top exchanges.
  • Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
  • Security: eToro is a regulated and licensed brokerage platform.
  • Buy other assets: Such as ETFs and cryptocurrencies.

Get $10 towards your stock purchase by creating an account with eToro now.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Open your brokerage account

Now that you've picked the best brokerage, it's time to fill out some personal info so you are able to invest in CLLS today.

How to Open a New Investment Account on eToro

  1. Click here to get started.
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
  2. Enter your personal data to open a new brokerage account.
  1. Submit your data by clicking the "Create Account" button.
  2. Get started with eToro today
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 3: Deposit funds into your brokerage account

Now that you've opened your account on a mobile trading app, you need to deposit funds:

Check out the walkthrough below for more details depositing funds into your investment account.

Get started with eToro today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 4: Analyze Cellectis Sa stock

Once you have chosen the best place to buy Cellectis Sa stock, it's critical to research their stock before you buy, so you truly understand the risk and upside.

Cellectis Sa shares at a glance

CLLS Price
$2.65
1w %
4.74%
1y %
30.22%
5y %
-85.39%
P/E
-1.61x
P/B
1.93x
P/S
6.04x
PEG
N/A
Revenue
$24.41M
Earnings
-$85.01M
Fore. Rev. Growth
55.61%
Fore. Earn. Growth
N/A
Market Cap
$147.30M
Next Earnings
May 8, 2024
Next Dividend
N/A

Cellectis Sa Overview

WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.

You can see all of the due diligence checks on CLLS's stock page.

Is CLLS stock undervalued?

Investors use a variety of different financial metrics, analyses, models, and charts to gauge CLLS's intrinsic value.

Using relative valuations methods:

  • CLLS could be undervalued based on its P/B ratio of 1.93x, relative to Biotechnology industry P/B ratio of 6.21x

You can access more valuation research on CLLS's stock here.

CLLS Financial Health Overview

Passed Health Checks:

  • CLLS has cash burn of 66032000. It has sufficient cash and short-term investments to cover this for at least one year.
  • CLLS has $67.36M in cash and short term investments. This is sufficient to cover its annual cash burn of $66.03M.
  • There are more short-term assets than short-term liabilities on the CLLS balance sheet.
  • There are more short-term assets than long-term liabilities on the CLLS balance sheet.

Failed Health Checks:

  • CLLS has a relatively high debt to equity ratio of 1.76.
  • Total CLLS debt is higher than 5 years ago, relative to shareholder equity.
  • CLLS profit margin has gone down from 1,627.8% to -348.3% in the past year.

Is it a good time to buy Cellectis Sa stock, according to analysts?

Out of 1 Equities analysts who give recommendations on CLLS, the consensus analyst rating on CLLS is a Buy

Please note that analyst ratings are not recommendations, nor are they investment advice.

You can dive deeper into what analysts are saying on the Cellectis Sa stock forecast page.

Metrics for Advanced CLLS Traders

SMA10
2.54
SMA20
2.54
SMA50
2.73
SMA100
2.84
SMA200
2.33
MACD
-0.04
MACD Signal
-0.07
MACD Histogram
0.03
RSI
52.06
Stochastic %K
66.86
Stochastic %D
57.69
StochRSI %K
96.3
StochRSI %D
95.36

CLLS Performance Metrics

Last year, CLLS revenue was $24.41M. During the last 5 year, CLLS's revenue has grown by -0.84% per year. This was slower than the Biotechnology industry average of 29.51%.

Learn more about CLLS's earnings and revenue performance here.

Who is buying/selling CLLS?

Over the last 12 months, executives and large shareholders at CLLS have not bought or sold any shares.

Research more about who owns CLLS shares here.

Does CLLS provide a stable income stream?

No, Cellectis Sa doesn't provide an income stream by paying out dividends.

CLLS Social Trading Data

One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.

Click below to find out what other traders have to say.

Step 5: Execute your CLLS trade

You have two primary types of orders:

  • Market order: A market order is an order to buy or sell a security at the best possible price.
    Market orders are generally the easiest way to buy.
  • Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
    If you want to make sure you're buying or selling at a specific price, use a limit order.

Hit the Open button and your broker will execute the order.

If you need additional assistance investing in stocks on eToro, click the how to video below:

Open eToro Account

Step 6: Keep tabs on your CLLS investment

Now that you own some CLLS shares, you'll want to keep up with your new investment.

Put CLLS on a watchlist to get notified of important updates regarding your CLLS stock.

CLLS Feed

How to Buy Stock in Cellectis Sa

To reiterate, here are the 6 steps for buying Cellectis Sa stock:

  1. Choose where to buy Cellectis Sa stock
  2. Open your brokerage account
  3. Deposit funds into your brokerage account
  4. Analyze Cellectis Sa stock
  5. Execute your CLLS trade
  6. Keep tabs on your CLLS investment

If you need a online brokerage, eToro is our favorite option.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

If you would like to get the latest scoop on your new investment in Cellectis Sa, hit the button below to create your watchlist.

NASDAQ: CLLS
$2.65-0.02 (-0.75%)
Updated Mar 28, 2024
Open eToro Account
NASDAQ: CLLS
$2.65-0.02 (-0.75%)
Updated Mar 28, 2024
Open eToro Account

FAQ

How much does it cost to buy one Cellectis Sa share?

As of Mar 28, 2024, it costs $2.65 to buy one share of Cellectis Sa stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $1, you can buy 0.377 shares of CLLS.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Is now a good time to buy Cellectis Sa stock?

According to 1 Wall Street analysts who monitor Cellectis Sa, their consensus recommendation is to buy Cellectis Sa stock.

What is the best way to buy Cellectis Sa stock?

One way to place an order for Cellectis Sa stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.